Since 2003, we have used fludarabine combined with a middle dose of Ara-C, mitoxantrone and granulocyte-colony stimulating factor (G-CSF) as a salvage regimen for patients with relapsed AML in China. This evidence concerns the gene CSF3 and acute myeloid leukemia.